Synmosa Biopharma (ROCO:4114) Margin of Safety % (DCF Earnings Based) : 35.92% (As of May. 07, 2025)

View and export this data going back to 2003. Start your Free Trial

What is Synmosa Biopharma Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2025-05-07), Synmosa Biopharma's Predictability Rank is 2-Stars. Synmosa Biopharma's intrinsic value calculated from the Discounted Earnings model is NT$50.25 and current share price is NT$32.20. Consequently,

Synmosa Biopharma's Margin of Safety % (DCF Earnings Based) using Discounted Earnings model is 35.92%.

Competitive Comparison of Synmosa Biopharma's Margin of Safety % (DCF Earnings Based)

For the Drug Manufacturers - Specialty & Generic subindustry, Synmosa Biopharma's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synmosa Biopharma's Margin of Safety % (DCF Earnings Based) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Synmosa Biopharma's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Synmosa Biopharma's Margin of Safety % (DCF Earnings Based) falls into.

Save Embed

;

Save Embed

;

Synmosa Biopharma Margin of Safety % (DCF Earnings Based) Calculation

Synmosa Biopharma's Margin of Safety % (DCF Earnings Based) for today is calculated as

Margin of Safety % (DCF Earnings Based)	=	(Intrinsic Value: DCF (Earnings Based)	-	Current Price)	/	Intrinsic Value: DCF (Earnings Based)
	=	(50.25	-	32.20)	/	50.25
	=	35.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow.

Synmosa Biopharma Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Synmosa Biopharma's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Synmosa Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synmosa Biopharma Corp (ROCO:4114) » Definitions » Margin of Safety % (DCF Earnings Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 6, Gongye 1st Road, Hukou Township, Hsinchu County, Hsinchu, TWN

Website

https://www.synmosa.com.tw

Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.

Synmosa Biopharma Headlines

No Headlines